Never miss an Axios exclusive. Sign up for Mike Allen's AM newsletter.

The importance of diversity in clinical trials

Clinical trials don’t enroll enough black participants, even when they’re testing drugs for treatments that disproportionately affect African-Americans, according to a ProPublica analysis.

Why it matters: It’s not entirely clear why some diseases affect different populations differently, but those differences are an important part of understanding whether a particular treatment is safe and effective — exactly what clinical trials are supposed to test.

By the numbers: In most of the trials ProPublica surveyed, fewer than 5% of participants were black — compared with more than 13% of the U.S. population.

The results weren’t much better even for treatments that could disproportionately benefit black people, such as multiple myeloma and prostate cancer. These are more prevalent among African-Americans, yet black enrollment in trials for those drugs still often sat around 2% or 3%.